Soft Tissue Sarcoma Lung Metastases Epidemiology Forecast
DelveInsight’s ‘Soft Tisue Sarcoma (STS) with lung metastases—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the STS with lung metastases, historical and forecasted epidemiology as well as the STS with lung metastases trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2017–2030
STS with lung metastases Disease Understanding
Soft tissue sarcoma is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves). These cancers can develop anywhere in the body but are found mostly in the arms, legs, chest, and abdomen. The lung is the most frequent site of metastasis from soft-tissue sarcomas. From several studies, it has been estimated that around 50–60% of the STS cases develop lung metastases.
STS with lung metastases Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total incident cases of Soft tissue sarcoma, Total incident cases of STS with lung metastases, Gender-specific incident cases of STS with lung metastases, and Subtype-specific incident cases of STS with lung metastases scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.
STS with lung metastases Detailed Epidemiology Segmentation
- As per DelveInsight estimates, the incident cases of STS with lung metastases in the 7MM was 7,871 cases in 2017.
- Among the EU5, Germany had the highest incident population in 2017 (1,308 cases), followed by France
- Females accounted for a larger percentage among the STS with lung metastases cases as compared to males. In 2017, a lower number of males were affected by this disease, i.e., 42% of the total incident cases of STS with lung metastases population in the United States, which is equivalent to 1,053 cases. In comparison to this, for females, the number of cases observed was 1,454 in 2017.
- Among the total incidence of STS with lung metastases cases in the United States, there were 777 cases of Leiomyosarcoma, and 150 cases of liposarcoma, followed by synovial with 376 cases and other types with 1,203 cases.
- The incident population of STS with lung metastases in Japan is increasing at a CAGR rate of 1.18%, during the study period
Scope of the Report
- The report covers the descriptive overview of STS with lung metastases, explaining its causes, symptoms, pathophysiology, and genetic basis.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of STS with lung metastases.
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM by Total incident cases of Soft tissue sarcoma, Total incident cases of STS with lung metastases, Gender-specific incident cases of STS with lung metastases, and Subtype-specific incident cases of STS with lung metastases.
Report Highlights
- 11-Year Forecast of STS with lung metastases
- 7MM Coverage
- Total incident cases of Soft tissue sarcoma
- Total incident cases of STS with lung metastases
- Gender-specific incident cases of STS with lung metastases
- Subtype-specific incident cases of STS with lung metastases
Key Questions Answered
- What is the disease risk, burden, and unmet needs of STS with lung metastases?
- What is the historical STS with lung metastases patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of STS with lung metastases at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to STS with lung metastases?
- Out of the above-mentioned countries, which country would have the highest incident population of STS with lung metastases during the forecast period (2020–2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?
Reasons to buy
The STS with lung metastases report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the 7MM STS with lung metastases epidemiology forecast.
- The STS with lung metastases epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
- The STS with lung metastases epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
1 Key Insights
2 Executive Summary of STS with lung metastases
3 Disease Background and Overview: STS with lung metastases
3.1 Introduction
3.2 General symptoms of lung metastases
3.3 Prognostic factors
3.3.1 Histology
3.3.2 Disease-free interval (DFI)
3.3.3 Completeness of resection
3.3.4 Response to chemotherapy
3.4 Staging System
3.5 Diagnosis of Soft-Tissue Sarcomas with Lung Metastases
4 Epidemiology and Patient Population
4.1 Key Findings
4.2 Epidemiology Methodology
4.3 Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM
4.4 Total Incident Cases of STS with lung metastases in the 7MM
5 United States Epidemiology
5.1 Assumptions and Rationale
5.2 Total Incident cases of Soft tissue sarcoma (STS) in the United States
5.3 Total incident cases of STS with lung metastases in the United States
5.4 Gender-specific incident cases of STS with lung metastases in the United States
5.5 Subtype-specific incident cases of STS with lung metastases in the United States
6 EU5 Epidemiology
6.1 Assumptions and Rationale
6.2 Germany Epidemiology
6.2.1 Total incident cases of Soft tissue sarcoma (STS) in Germany
6.2.2 Total incident cases of STS with lung metastases in Germany
6.2.3 Gender-specific incident cases of STS with lung metastases in Germany
6.2.4 Subtype-specific incident cases of STS with lung metastases in Germany
6.3 France Epidemiology
6.3.1 Total incident cases of Soft tissue sarcoma (STS) in France
6.3.2 Total incident cases of STS with lung metastases in France
6.3.3 Gender-specific incident cases of STS with lung metastases in France
6.3.4 Subtype-specific incident cases of STS with lung metastases (%) in France
6.4 Italy Epidemiology
6.4.1 Total incident cases of Soft tissue sarcoma (STS) in Italy
6.4.2 Total incident cases of STS with lung metastases in Italy
6.4.3 Gender-specific incident cases of STS with lung metastases in Italy
6.4.4 Subtype-specific incident cases of STS with lung metastases in Italy
6.5 Spain Epidemiology
6.5.1 Total incident cases of Soft tissue sarcoma (STS) in Spain
6.5.2 Total incident cases of STS with lung metastases in Spain
6.5.3 Gender-specific incident cases of STS with lung metastases in Spain
6.5.4 Subtype-specific incident cases of STS with lung metastases (%) in Spain
6.6 United Kingdom Epidemiology
6.6.1 Total incident cases of Soft tissue sarcoma (STS) in the United Kingdom
6.6.2 Total incident cases of STS with lung metastases in the UK
6.6.3 Gender-specific incident cases of STS with lung metastases in the UK
6.6.4 Subtype-specific incident cases of STS with lung metastases in the UK
7 Japan Epidemiology
7.1 Assumptions and Rationale
7.1.1 Total incident cases of Soft tissue sarcoma (STS) in Japan
7.1.2 Total incident cases of STS with lung metastases in Japan
7.1.3 Gender-specific incident cases of STS with lung metastases in Japan
7.1.4 Subtype-specific incident cases of STS with lung metastases (%) in Japan
8 Appendix
8.1 Bibliography
8.2 Report Methodology
9 DelveInsight Capabilities
10 Disclaimer
11 About DelveInsight
List of Table
Table 1: Summary of STS with lung metastases, Epidemiology and Key Events (2017–2030)
Table 2: Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM (2017–2030)
Table 3: Total Incident Cases of STS with lung metastases in the 7MM (2017–2030)
Table 4: Total Incident cases of STS (Soft tissue sarcoma) in the United States (2017–2030)
Table 5: Total incident cases of STS with lung metastases in the United States (2017–2030)
Table 6: Gender-specific incident cases of STS with lung metastases in the US (2017–2030)
Table 7: Subtype-specific incident cases of STS with lung metastases in the US (2017–2030)
Table 8: Total incident cases of Soft tissue sarcoma (STS) in Germany (2017–2030)
Table 9: Total incident cases of STS with lung metastases in Germany (2017–2030)
Table 10: Gender-specific incident cases of STS with lung metastases in Germany (2017–2030)
Table 11: Subtype-specific incident cases of STS with lung metastases in Germany (2017–2030)
Table 12: Total incident cases of Soft tissue sarcoma (STS) in France (2017–2030)
Table 13: Total incident cases of STS with lung metastases in France (2017–2030)
Table 14: Gender-specific incident cases of STS with lung metastases in France (2017–2030)
Table 15: Subtype-specific incident cases of STS with lung metastases in France (2017–2030)
Table 16: Total incident cases of Soft tissue sarcoma (STS) in Italy (2017–2030)
Table 17: Total incident cases of STS with lung metastases in Italy (2017–2030)
Table 18: Gender-specific incident cases of STS with lung metastases in Italy (2017–2030)
Table 19: Subtype-specific incident cases of STS with lung metastases in Italy (2017–2030)
Table 20: Total incident cases of Soft tissue sarcoma (STS) in Spain (2017–2030)
Table 21: Total incident cases of STS with lung metastases in Spain (2017–2030)
Table 22: Gender-specific incident cases of STS with lung metastases in Spain (2017–2030)
Table 23: Subtype-specific incident cases of STS with lung metastases in Spain (2017–2030)
Table 24: Total incident cases of Soft tissue sarcoma (STS) in the UK (2017–2030)
Table 25: Total incident cases of STS with lung metastases in the UK (2017–2030)
Table 26: Gender-specific incident cases of STS with lung metastases in the UK (2017–2030)
Table 27: Subtype-specific incident cases of STS with lung metastases in the UK (2017–2030)
Table 28: Total incident cases of Soft tissue sarcoma (STS) in Japan (2017–2030)
Table 29: Total incident cases of STS with lung metastases in Japan (2017–2030)
Table 30: Gender-specific incident cases of STS with lung metastases in Japan (2017–2030)
Table 31: Subtype-specific incident cases of STS with lung metastases in Japan (2017–2030)
List of Figures
Figure 1: Diagnosis of Soft-Tissue Sarcoma with Lung Metastases
Figure 2: Imaging Tests for Soft-Tissue Sarcoma (STS)
Figure 3: Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM (2017–2030)
Figure 4: Total Incident Cases of STS with lung metastases in the 7MM (2017–2030)
Figure 5: Total Incident cases of STS (Soft tissue sarcoma) in the United States (2017–2030)
Figure 6: Total incident cases of STS with lung metastases in the United States (2017–2030)
Figure 7: Gender-specific incident cases of STS with lung metastases in the US (2017–2030)
Figure 8: Subtype-specific incident cases of STS with lung metastases in the US (2017–2030)
Figure 9: Total incident cases of Soft tissue sarcoma (STS) in Germany (2017–2030)
Figure 10: Total incident cases of STS with lung metastases in Germany (2017–2030)
Figure 11: Gender-specific incident cases of STS with lung metastases in Germany (2017–2030)
Figure 12: Subtype-specific incident cases of STS with lung metastases in Germany (2017–2030)
Figure 13: Total incident cases of Soft tissue sarcoma (STS) in France (2017–2030)
Figure 14: Total incident cases of STS with lung metastases in France (2017–2030)
Figure 15: Gender-specific incident cases of STS with lung metastases in France (2017–2030)
Figure 16: Subtype-specific incident cases of STS with lung metastases in France (2017–2030)
Figure 17: Total incident cases of Soft tissue sarcoma (STS) in Italy (2017–2030)
Figure 18: Total incident cases of STS with lung metastases in Italy (2017–2030)
Figure 19: Gender-specific incident cases of STS with lung metastases in Italy (2017–2030)
Figure 20: Subtype-specific incident cases of STS with lung metastases in Italy (2017–2030)
Figure 21: Total incident cases of Soft tissue sarcoma (STS) in Spain (2017–2030)
Figure 22: Total incident cases of STS with lung metastases in Spain (2017–2030)
Figure 23: Gender-specific incident cases of STS with lung metastases in Spain (2017–2030)
Figure 24: Subtype-specific incident cases of STS with lung metastases in Spain (2017–2030)
Figure 25: Total incident cases of Soft tissue sarcoma (STS) in the UK (2017–2030)
Figure 26: Total incident cases of STS with lung metastases in the UK (2017–2030)
Figure 27: Gender-specific incident cases of STS with lung metastases in the UK (2017–2030)
Figure 28: Subtype-specific incident cases of STS with lung metastases in the UK (2017–2030)
Figure 29: Total incident cases of Soft tissue sarcoma (STS) in Japan (2017–2030)
Figure 30: Total incident cases of STS with lung metastases in Japan (2017–2030)
Figure 31: Gender-specific incident cases of STS with lung metastases in Japan (2017–2030)
Figure 32: Subtype-specific incident cases of STS with lung metastases in Japan (2017–2030)